Novartis considers selling its $5B+ ophthalmology and respiratory units — report – Endpoints News

As No­var­tis has been fo­cus­ing its core pipeline, and spin­ning off its gener­ics arm San­doz, the com­pa­ny may be look­ing to sell even more.
Ac­cord­ing to a re­port from Bloomberg to­day, the Swiss phar­ma is con­sid­er­ing the sale of some of its “non-core” as­sets to raise funds to in­vest in “cut­ting-edge med­i­cines,” peo­ple fa­mil­iar with the mat­ter said.
The re­port elab­o­rates that No­var­tis is in the ear­ly phas­es of “con­sid­er­ing op­tions” for its res­pi­ra­to­ry and oph­thal­mol­o­gy units, which wouldn’t close un­til af­ter San­doz spins out, with anony­mous sources telling the pub­li­ca­tion that pri­vate eq­ui­ty firms could spend up to $5 bil­lion on the oph­thal­mol­o­gy unit alone, ac­cord­ing to Bloomberg.
No­var­tis’ oph­thal­mol­o­gy unit, which down­sized in 2019 with the spin­out of Al­con’s eye busi­ness, shift­ed its fo­cus to de­vel­op­ing com­pounds to pro­tect and re­store vi­sion, with its re­search pri­or­i­ties in­clud­ing dis­eases such as glau­co­ma and age-re­lat­ed mac­u­lar de­gen­er­a­tion. For the res­pi­ra­to­ry unit, No­var­tis is de­vel­op­ing ther­a­pies to counter dis­eases such as COPD and asth­ma.
End­points News reached out to No­var­tis but did not re­ceive a com­ment by press time.
If this move is go­ing for­ward, it comes at a time when No­var­tis is mak­ing some ma­jor changes. The com­pa­ny de­cid­ed to spin out its gener­ic arm, San­doz, in­to a sep­a­rate com­pa­ny, which No­var­tis plans to com­plete in the sec­ond half of next year.
Mean­while, any move on the two units will most like­ly hap­pen af­ter the San­doz spin­out is com­plet­ed next year.
This would not be the first time that No­var­tis has spun off some­thing re­lat­ed to the eye. In 2019, the phar­ma spun off its eye care unit Al­con in­to its own busi­ness, which No­var­tis orig­i­nal­ly put up $770 mil­lion to ac­quire. Al­con has since gone on to char­ter its own path and even take a swing at the dry eye mar­ket ear­li­er this year.
If No­var­tis does sell these two units, the sales would come on the back of a ma­jor re­struc­tur­ing, which may en­act $1 bil­lion in cuts and bring the phar­ma­ceu­ti­cal and on­col­o­gy units un­der one roof.
Key takeaways:
The cell and gene market still faces a lack of cohesion across stakeholders when it comes to classification of products
Expertise is in disparate pockets across the FDA, making it challenging to plan review teams
Regulators and policymakers are placing greater emphasis on accurate and diverse representation in trial populations
Tailoring an effective evidence-generation plan at the clinical phase is vital for ensuring ongoing evidence generation remains informative into product life cycle
Midterm elections mean committee leadership shake-ups, and for the most powerful health committee in Congress that includes changes for both the chair and the ranking member as Democrats are likely to cling to control of the Senate.
The current chair of the Senate health, education, labor and pensions (HELP) committee, Patty Murray (D-WA), said this week that she’s switching gears and seeking the top slot on the powerful Appropriations committee.
Unlock this story instantly and join 154,100+ biopharma pros reading Endpoints daily — and it’s free.
The infamous short seller who went after Ginkgo Bioworks last year has a new target in its sights.
Scorpion Capital released a 236-page report Tuesday morning focused on Twist Bioscience, the synbio startup led by Emily Leproust that’s trading down $TWST more than 27%. The release wiped hundreds of millions of dollars in market capital and almost 67% since January 1.
We are short $TWST Twist Bioscience. Report now live at Our third “synthetic biology” short report in a year after $BLI and $DNA. The latest miniaturized “lab-on-a-chip” scam, like Theranos, Berkeley Lights, and other failures – and a ticking time bomb.
Five years after shelling out more than $5 billion for Ariad Pharmaceuticals and its rare leukemia drug Iclusig, Takeda is setting plans in motion for a potential label expansion into the first-line setting — but for now, the pharma giant is keeping its cards close.
Iclusig and reduced intensity chemotherapy successfully beat out Novartis’ Gleevec in treating newly diagnosed patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in the Phase III PhALLCON trial, Takeda announced on Thursday.
The emergence of interchangeable biosimilars since the pathway opened up has been slow. But the FDA on Thursday approved the fourth interchangeable biosimilar, which is also the second interchangeable biosimilar insulin product.
Eli Lilly’s Rezvoglar (insulin glargine-aglr), which converted to an interchangeable after an earlier biosimilar approval in December 2021, follows Viatris’ Semglee in seeking out a niche to compete with Sanofi’s blockbuster Lantus (insulin glargine).
Just over a month after CDER director Patrizia Cavazzoni made clear that she and FDA were looking to shut down Vanda Pharmaceuticals’ sNDA request, the biotech is calling foul.
Vanda attorney Paul Hughes submitted a letter to FDA last week asking the agency to follow federal statute and set up a hearing regarding its sNDA by no later than Christmas Eve.
The request follows FDA’s rejection in August of the sNDA for Hetlioz (tasimelteon) as a treatment of jet lag disorder, on which Vanda said it accepted the opportunity for a hearing. Vanda has already sued the FDA twice for this delayed hearing.
Unlock this story instantly and join 154,100+ biopharma pros reading Endpoints daily — and it’s free.
Using patient health records to reach physicians is a common marketing tactic for pharma companies. However, improved data analysis and artificial intelligence are now moving the goalposts from “here’s a brand” to “here’s a brand that we know your patient could use right now.”
OptimizeRx is using its predictive analytics for marketing and digital point of care to send very targeted messages to doctors right inside patients’ electronic health records (EHRs).
Unlock this story instantly and join 154,100+ biopharma pros reading Endpoints daily — and it’s free.
Will the pandemic be a turning point for drug and vaccine access around the world? That depends on pharma’s next steps, according to the latest biennial report by the Access to Medicine Foundation.
The Bill and Melinda Gates Foundation-backed group noted “industry-wide” progress since its last report, led by GSK, which kept its first-place accessibility ranking for the eighth time. However, the foundation also reported that low-income countries remain “widely overlooked,” and many dangerous diseases are going unaddressed.
Unlock this story instantly and join 154,100+ biopharma pros reading Endpoints daily — and it’s free.
FDA Commissioner Rob Califf sat down for a conversation on Thursday morning with Rick Pazdur, head of the FDA’s Oncology Center of Excellence, with the two agreeing that accelerated approval reforms need to happen, that multi-regional clinical trials are always better than single-country trials, and that returning every last FDAer to the White Oak campus doesn’t make sense.
The conversation, conducted as part of the Friends of Cancer Research’s annual meeting, began with Califf’s questions on the empty space around White Oak as routine staff have mostly moved their operations to the more versatile virtual setting, and as advisory committee and all industry meetings remain virtual.
Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas<!–
2029 Becker Drive,
(785) 813-1733 –>
© Endpoints Company 2022
If you’re already an Endpoints subscriber, enter your email below for a magic link that lets you log in quickly without using a password. Please note the magic link is one-time use only and expires after 24 hours.
We’ll e-mail you a link to set a new password. Please note this link is one-time use only and is valid for only 24 hours.


Leave a Reply

Your email address will not be published.